ClinicalTrials.gg
Active, not recruitingNCT04565015Updated Jul 25, 2025

Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency

A Phase 3 interventional study of GC5107 in Primary Immune Deficiency, sponsored by GC Biopharma Corp. Active, not recruiting at 8 sites in 3 countries. Open to participants aged 2 Years to 16 Years. Per ClinicalTrials.gov, last updated 2025-07-25.

Sponsored by GC Biopharma Corp · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
2 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 108 studies in Primary Immunodeficiency Diseases with a site in United States — 25 open to participants now, 35 under way, 4 of them phase 3. Primary Immunodeficiency Diseases · United States.

Planned enrollment
52nd of 75
24 · median 40
Started
2020
with 8 others
Phase 3
30 of 108
none open now
Primary completion
2026-05
later than 3 of 29 live
Registered
84th of 108
by date

Among the 108 studies in Primary Immunodeficiency Diseases with a site in United States, this one is the 52nd largest by planned enrollment of the 75 interventional ones that give a count, is one of 9 that started in 2020, is one of 30 in phase 3, reaches primary completion later than 3 of the 29 other live ones, and was the 84th registered.

Primary Immunodeficiency Diseases

211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.

Browse Primary Immunodeficiency Diseases studies →

Open to participants now

25 of the 108 studies in Primary Immunodeficiency Diseases with a site in United States are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.

This study: 2 Years to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 108 studies in Primary Immunodeficiency Diseases with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the pharmacokinetics and safety of Immune Globulin Intravenous (Human) GC5107 in pediatric subjects with Primary Humoral Immunodeficiency (PHID).

Read the detailed description

This is a prospective, open-label, single-arm, historically controlled, multi-center Phase III study to assess the pharmacokinetics and safety of Immune Globulin Intravenous (Human) GC5107 in pediatric subjects aged ≥ 2 years and \< 17 years with PHID.

Subjects will receive intravenous infusions of the investigational product at the same dose and interval as used for their previous Immunoglobulin intravenous (IGIV) maintenance therapy. GC5107 will be infused every 21 or 28 days for a period of 12 months.

03

Conditions studied

  • Primary Immune Deficiency
04

Who can participate

Ages eligible
2 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must be ≥ 2 to \< 17 years of age, at the time of signing the
  • Pediatric subject has a confirmed and documented clinical diagnosis of Primary Humoral Immunodeficiency, including hypogammaglobulinemia or agammaglobulinemia
  • Subject who has received 300 - 900 mg/kg of IGIV therapy at 21 or 28 day intervals for at least 3 months prior to this study
  • Subject who has at least 2 documented plasma IgG trough level of ≥ 500 mg/dL at two infusion cycles (21 or 28 days) within 12 months prior to enrollment
  • Subject who is willing to comply with all requirements of the protocol

Exclusion criteria

Exclusion Criteria:

  • Subject who has a history of reactions or to IGIV or other injectable forms of IgG
  • Subject who has IgA deficiency and is known to have antibodies to IgA
  • Subject who has secondary immunodeficiency
  • Subject who has participated in another clinical study (other than an IGIV study) within 3 weeks prior to screening
  • Subject who has been diagnosed with dysgammaglobulinemia or isolated IgG subclass deficiency or isolated IgA deficiency, or who has clinically significant impairment of cellular or innate immunity at the discretion of the Investigator
  • Subject who has received blood products other than human albumin or human immune globulin within 6 months prior to enrollment
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    GC5107

    Immune Globulin Intravenous (Human), 10% Liquid

    Biological: GC5107

Interventions

  • BiologicalGC5107

    Intravenously infused at a dose of 300 - 900 mg per kg (of body weight) every 21 or 28 days for 12 months

    Also known as: GCC 10% IGIV, Immune Globulin Intravenous (Human), 10% Liquid

06

What researchers measure

Primary outcomes

  1. The Pharmacokinetic (PK) Plasma concentration-time curve of total IgG

    Time frame: before and after 5th infusion (12 or 16 weeks)

  2. The Pharmacokinetic (PK) Half-life of total IgG

    Time frame: before and after 5th infusion (12 or 16 weeks)

  3. The Pharmacokinetic (PK) Area under the curve of total IgG

    Time frame: before and after 5th infusion (12 or 16 weeks)

  4. The Pharmacokinetic (PK) Volume of distribution of total IgG

    Time frame: before and after 5th infusion (12 or 16 weeks)

  5. The Pharmacokinetic (PK) Maximum concentration of total IgG

    Time frame: before and after 5th infusion (12 or 16 weeks)

  6. The Pharmacokinetic (PK) Minimum concentration of total IgG

    Time frame: before and after 5th infusion (12 or 16 weeks)

  7. The Pharmacokinetic (PK) Time of maximum concentration of total IgG

    Time frame: before and after 5th infusion (12 or 16 weeks)

  8. The Pharmacokinetic (PK) Clearance of total IgG

    Time frame: before and after 5th infusion (12 or 16 weeks)

  9. Trough serum total IgG levels before each infusion of GC5107 in all subjects and the interval between infusions

    Time frame: 12 months

  10. The proportion of infusions with temporally associated adverse events (AEs) that occur during or within 1 hour, 24 hours, and 72 hours following an infusion of investigational product

    AEs that occur during or within 1 hour, 24 hours, and 72 hours following each infusion during 12 months of the study period

    Time frame: 12 months

Secondary outcomes

  1. The Pharmacokinetic (PK) Maximum concentration of IgG subclasses

    Time frame: before and after 5th infusion (12 or 16 weeks)

  2. The Pharmacokinetic (PK) Minimum concentration of IgG subclasses

    Time frame: before and after 5th infusion (12 or 16 weeks)

  3. The Pharmacokinetic (PK) Half-life of IgG subclasses

    Time frame: before and after 5th infusion (12 or 16 weeks)

  4. Trough serum level of IgG subclasses and specific IgG antibodies before Infusion 1 and 13 (for subjects on 28-day infusion schedule) or Infusion 1 and 17 (for subjects on 21-day infusion schedule)

    Time frame: 12 months

  5. Number and proportion of subjects who failed to meet the target IgG trough level (500 mg/dL) at any time point equal to or subsequent to 5th infusion (estimated 5 half-lives)

    Time frame: 12 months

  6. The overall incidence of all AEs that occur during or within 1 hour, 24 hours, and 72 hours following an infusion of investigational product

    AEs that occur during or within 1 hour, 24 hours, and 72 hours following each infusion during 12 months of the study period

    Time frame: 12 months

  7. The frequency of all AEs that occur during the study regardless of the investigator's assessment of their relationship to investigational product

    Time frame: 13 months (12 months of treatment + 1 month of follow-up)

  8. The frequency of suspected adverse reactions as defined by all AEs either classified as at least possibly related to GC5107

    Time frame: 13 months (12 months of treatment + 1 month of follow-up)

  9. The number and proportion of GC5107 infusions for which the infusion rate was decreased due to AEs

    Time frame: 12 months

  10. The proportion of AEs considered by the investigator to be investigational product related

    Time frame: 13 months (12 months of treatment + 1 month of follow-up)

  11. Viral safety (freedom from transmission of blood-borne viral diseases): the human immunodeficiency virus (HIV) type 1 & 2, hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), and parvovirus B19

    Time frame: 13 months (12 months of treatment + 1 month of follow-up)

Other outcomes

  1. The incidence of acute serious bacterial infections (aSBIs) defined at United States Food and Drug Administration (FDA) guidance criteria (bacterial pneumonia, bacteremia/sepsis, bacterial meningitis, visceral abscess, osteomyelitis/septic arthritis)

    Time frame: 13 months (12 months of treatment + 1 month of follow-up)

  2. The incidence of infections other than acute serious bacterial infections

    Time frame: 13 months (12 months of treatment + 1 month of follow-up)

  3. The number of days missed from work, school, kindergarten, day care or days unable to perform normal daily activities due to infections

    Time frame: 13 months (12 months of treatment + 1 month of follow-up)

  4. The number of days that the care provider of the pediatric subject had to miss work in order to care for the child due to infections

    Time frame: 13 months (12 months of treatment + 1 month of follow-up)

  5. The number of days of unscheduled physician visits due to infection

    Time frame: 13 months (12 months of treatment + 1 month of follow-up)

  6. The number of days of hospitalizations due to infection

    Time frame: 13 months (12 months of treatment + 1 month of follow-up)

  7. The number of days of intravenous (IV) therapeutic antibiotics

    Time frame: 13 months (12 months of treatment + 1 month of follow-up)

  8. The number of days of oral (PO) therapeutic antibiotics

    Time frame: 13 months (12 months of treatment + 1 month of follow-up)

  9. Time to resolution of infections

    Time frame: 13 months (12 months of treatment + 1 month of follow-up)

  10. The incidence of infections by trough IgG levels

    Time frame: 13 months (12 months of treatment + 1 month of follow-up)

  11. Episodes of fever (annual rate of fever episodes per subject)

    Time frame: 13 months (12 months of treatment + 1 month of follow-up)

07

Study locations

8 sites
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Immunoe Health & Research Centers
    Centennial, Colorado 80112, United States
  • Allergy Partners of North Texas Research
    Dallas, Texas 75230, United States
  • Lysosomal and Rare Disorders Research and Treatment Center, Inc.
    Fairfax, Virginia 22030, United States
  • Children's Hospital of Richmond at VCU
    Richmond, Virginia 23219, United States
  • University Clinical Center Sarajevo
    Sarajevo, Sarajevo 71000, Bosnia and Herzegovina
  • University clinical center Tuzla
    Tuzla, Tuzla 75000, Bosnia and Herzegovina
  • Institute for Child and Youth Health Care of Vojvodina
    Novi Sad, Novi Sad 21000, Serbia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2020 (actual). Primary completion is estimated for May 2026, 65 months after the start.

Of 25 phase 3 interventional studies under Primary Immunodeficiency Diseases, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 41. This study's planned 65 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2020
First posted
Sep 25, 2020
StartActual
Dec 21, 2020
Primary completionEst.
May 2026
CompletionEst.
Nov 2026
Last update
Jul 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04565015
Lead sponsor
GC Biopharma Corp
Collaborators
Atlantic Research Group
Responsible party
Sponsor
First posted
Sep 25, 2020
Start date
Dec 21, 2020
Primary completion
May 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Jul 25, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion